INZY vs. XOMA, ELYM, RAPT, XBIT, VSTM, XERS, CTMX, ENTA, AKBA, and NKTR
Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include XOMA (XOMA), Eliem Therapeutics (ELYM), RAPT Therapeutics (RAPT), XBiotech (XBIT), Verastem (VSTM), Xeris Biopharma (XERS), CytomX Therapeutics (CTMX), Enanta Pharmaceuticals (ENTA), Akebia Therapeutics (AKBA), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry.
Inozyme Pharma (NASDAQ:INZY) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
88.3% of Inozyme Pharma shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 11.9% of Inozyme Pharma shares are held by insiders. Comparatively, 7.2% of XOMA shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Inozyme Pharma has a net margin of 0.00% compared to XOMA's net margin of -886.91%. XOMA's return on equity of -25.17% beat Inozyme Pharma's return on equity.
XOMA has higher revenue and earnings than Inozyme Pharma. XOMA is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
Inozyme Pharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
In the previous week, Inozyme Pharma had 11 more articles in the media than XOMA. MarketBeat recorded 17 mentions for Inozyme Pharma and 6 mentions for XOMA. XOMA's average media sentiment score of 0.56 beat Inozyme Pharma's score of -0.25 indicating that XOMA is being referred to more favorably in the news media.
Inozyme Pharma presently has a consensus price target of $17.00, indicating a potential upside of 266.38%. XOMA has a consensus price target of $57.00, indicating a potential upside of 135.54%. Given Inozyme Pharma's higher probable upside, equities analysts clearly believe Inozyme Pharma is more favorable than XOMA.
XOMA received 395 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 81.40% of users gave Inozyme Pharma an outperform vote while only 65.95% of users gave XOMA an outperform vote.
Summary
Inozyme Pharma beats XOMA on 9 of the 16 factors compared between the two stocks.
Get Inozyme Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inozyme Pharma Competitors List
Related Companies and Tools
